TABLE 1.
Characteristics of the included studies.
| Study ID | Diagnostic criteria | Sample size | Course of disease (month) | Mean age (year) | Male Proportion(Male%) | Intervention | Course of treatment (week) | Outcomes | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trial | Control | Trial | Control | Trial | Control | Trial | Control | Trial | Control | ||||
| Deng et al. (2017) | CCMD-3 | 59 | 57 | 18.18 ±13.56 | 17.93 ±12.84 | 43.81 ±10.23 | 44.53 ±11.65 | 44.07% | 52.63% | XYS + C | Paroxetine | 4 | CER, HAMA-14, AER |
| Ding et al. (2013) | CCMD-3 | 37 | 38 | 25.15 ±10.84(day) | 27.21 ±6.72(day) | 29.46 ±6.82 | 27.62 ±4.24 | NR | NR | XYS + C | Buspirone + Lorazepam | 8 | CER, HAMA-14, SAS |
| Han et al. (2011) | CCMD-2R | 40 | 40 | 18–155 | 12–168 | 22–77 | 23–76 | 42.50% | 37.50% | XYS + C | Deanxit | 12 | CER, HAMA-14 |
| Li and Qin (2016) | CCMD-3 | 32 | 32 | 57.6 ±28.8 | 58.8 ±30.0 | 41.6 ±7.8 | 42.1 ±7.2 | 46.88% | 43.75% | XYS + C | Buspirone | 6 | CER, HAMA-14, TESS |
| Li et al. (2022) | CCMD-3 | 40 | 40 | ≥1 | ≥1 | 48.50 ± 1.25 | 46.00 ± 1.06 | 42.50% | 40.00% | XYS + C | Buspirone | 6 | CER, HAMA-14, AER |
| Lv et al. (2013) | CCMD-3 | 36 | 35 | 12.3 ±NR | 11.2 ±NR | 35.5 ±NR | 34.4 ±NR | 33.30% | 40.00% | XYS + C | Deanxit + psychological counseling | 8 | CER, HAMA-14 |
| Wang (2014) | CCMD-3 | 30 | 30 | 18–204 | 12–180 | 21–75 | 23–72 | 33.30% | 40.00% | XYS + C | Paroxetine | 8 | CER, HAMA-14 |
| Wang et al. (2010) | CCMD-3 | 30 | 30 | NR | NR | 48 ±NR | 51 ±NR | 53.33% | 50.00% | XYS + C | Deanxit | 6 | CER, HAMA-14 |
| Xiong and Song. (2019) | CCMD-3 | 100 | 100 | NR | NR | 57.8 ±6.5 | 55.4 ±6.2 | 65.00% | 62.00% | XYS + C | Deanxit(+Tandospirone for severe patients) | 8 | CER, HAMA-14, AER, PSQI |
| Zhou et al. (2019) | CCMD-3 | 35 | 35 | 4.37 ±2.52 | 4.37 ±2.52 | 44.86 ±10.81 | 46.29 ±12.28 | 34.29% | 28.57% | XYS + C | Mirtazapine | 4 | CER, HAMA-14, AER, PSQI |
| Zhu (2015) | CCMD-3 | 28 | 28 | 61.68 ±29.52 | 61.68 ±29.52 | 42.86 ±14.12 | 42.86 ±14.12 | NR | NR | XYS + C | Buspirone | 6 | CER, HAMA-14, TESS |
| Chen and (2016) | DSM-IV | 78 | 76 | 23.28 ±5.72 | 23.12 ±3.37 | 43.65 ±8.01 | 43.93 ±10.54 | 49.38% | 51.28% | XYS | Deanxit | 6 | CER, HAMA-14, SAS |
| Li et al. (2017) | CCMD-3 | 48 | 42 | 17.86 ±7.34 | 17.76 ±7.84 | 55.15 ±11.50 | 54.71 ±10.77 | 39.58% | 42.86% | XYS | Lorazepam | 4 | CER, HAMA-14, AER, TESS |
| Shi (2018) | ICD-10 | 40 | 40 | NR | NR | 33.4 ±12.8 | 34.3 ±12.4 | 47.50% | 45.00% | XYS | Deanxit | 4 | CER, HAMA-14 |
Abbreviations: AER, adverse events rates; CCMD, Chinese classification of mental disorders; CER, clinical efficacy rates; DSM, diagnostic and statistical manual of mental disorders; ER, efficacy rates; HAMA-14, Hamilton Anxiety Scale-14; ICD, international statistical classification of diseases and related health problems; NR, not reported; PSQI, pittsburgh sleep quality index; SAS, Self-Rating Anxiety Scale; TESS, treatment emergent symptom scale.